Citadel Advisors LLC purchased a new stake in Mirati Therapeutics, Inc. (NASDAQ:MRTX) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 22,855 shares of the biotechnology company’s stock, valued at approximately $268,000. Citadel Advisors LLC owned about 0.09% of Mirati Therapeutics as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also modified their holdings of the stock. Broadfin Capital LLC raised its stake in Mirati Therapeutics by 19.1% during the second quarter. Broadfin Capital LLC now owns 2,490,801 shares of the biotechnology company’s stock valued at $9,091,000 after buying an additional 400,000 shares in the last quarter. Sabby Management LLC raised its stake in Mirati Therapeutics by 2.1% during the second quarter. Sabby Management LLC now owns 255,100 shares of the biotechnology company’s stock valued at $921,000 after buying an additional 5,365 shares in the last quarter. Royce & Associates LP raised its stake in Mirati Therapeutics by 88.7% during the second quarter. Royce & Associates LP now owns 251,100 shares of the biotechnology company’s stock valued at $917,000 after buying an additional 118,063 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Mirati Therapeutics by 53.3% during the second quarter. Dimensional Fund Advisors LP now owns 199,563 shares of the biotechnology company’s stock valued at $728,000 after buying an additional 69,377 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new stake in Mirati Therapeutics during the first quarter valued at approximately $854,000. 64.73% of the stock is owned by hedge funds and other institutional investors.

In other Mirati Therapeutics news, major shareholder Venbio Select Advisor Llc bought 650,000 shares of the stock in a transaction that occurred on Thursday, November 16th. The shares were purchased at an average cost of $13.00 per share, for a total transaction of $8,450,000.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Jamie Christensen sold 7,499 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $14.00, for a total value of $104,986.00. Following the completion of the sale, the senior vice president now owns 10,169 shares in the company, valued at $142,366. The disclosure for this sale can be found here. Insiders have sold a total of 22,774 shares of company stock worth $356,586 over the last quarter. Insiders own 5.10% of the company’s stock.

Shares of Mirati Therapeutics, Inc. (MRTX) opened at $17.30 on Friday. Mirati Therapeutics, Inc. has a 1 year low of $2.70 and a 1 year high of $19.25.

Mirati Therapeutics (NASDAQ:MRTX) last announced its quarterly earnings results on Wednesday, November 1st. The biotechnology company reported ($0.65) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.16. sell-side analysts anticipate that Mirati Therapeutics, Inc. will post -2.77 EPS for the current year.

MRTX has been the topic of several research reports. Zacks Investment Research cut Mirati Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, October 5th. HC Wainwright reiterated a “buy” rating on shares of Mirati Therapeutics in a research report on Tuesday, November 7th. ValuEngine upgraded Mirati Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Friday, September 15th. Oppenheimer assumed coverage on Mirati Therapeutics in a research report on Monday, September 18th. They set an “outperform” rating and a $18.00 price target on the stock. Finally, Leerink Swann upgraded Mirati Therapeutics from a “market perform” rating to an “outperform” rating and set a $9.00 price target on the stock in a research report on Tuesday, November 14th. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $13.71.

COPYRIGHT VIOLATION WARNING: This article was first reported by Watch List News and is the property of of Watch List News. If you are accessing this article on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark law. The legal version of this article can be viewed at https://www.watchlistnews.com/citadel-advisors-llc-takes-268000-position-in-mirati-therapeutics-inc-mrtx/1765189.html.

About Mirati Therapeutics

Mirati Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of oncology products. The company’s clinical stage product candidates include glesatinib, an orally-bioavailable, potent, small molecule kinase inhibitor that is in Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC) patients with genetic alterations of MET; and in Phase Ib clinical trials in patients with genetic alterations of MET and Axl in NSCLC and other solid tumors.

Institutional Ownership by Quarter for Mirati Therapeutics (NASDAQ:MRTX)

Receive News & Ratings for Mirati Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.